Social Media Declared the BPC-157 Human Trial 'Launched' Months Before Enrollment Begins
Social Media Declared the BPC-157 Human Trial 'Launched' Months Before Enrollment Begins
On September 25, Max Swiergol, a blogger who covers evidence-based medicine, wrote that the University of Arkansas had 'just launched' the first randomized, placebo-controlled trial of injectable BPC-157 in the United States. Biomedical researcher Avi Roy checked the claim against the official clinical trials registry and showed that patient enrollment is not scheduled to begin until January 2027 at the earliest, with initial results expected no sooner than August of that year.
BPC-157 is a synthetic 15-amino-acid peptide originally isolated from human gastric juice. For years, people seeking faster healing of tendon, joint, and muscle injuries have been injecting it, even though no regulatory agency anywhere in the world has approved it as a drug. Swiergol's post accumulated 970,000 views, 1,100 likes, and 168 reposts, and it contradicts itself:
"The University of Arkansas just launched the first randomized, controlled trial of injectable BPC-157 in the U.S.... Participant enrollment will begin in early 2027. Initial data are expected no sooner than early 2028."
The word "launched" appears in the same post as enrollment no earlier than early 2027 and data no sooner than early 2028. The following day, September 26, another health account, Hims House, repeated the same "trial is already underway" framing. Both authors read the registry listing as an announcement that treatment had begun.
On September 27, Avi Roy opened the study record on ClinicalTrials.gov: the official status is "not yet recruiting." The design calls for 20 to 30 patients who have undergone rotator cuff surgery (repair of the shoulder tendons); for 90 consecutive days they will self-administer subcutaneous injections of either BPC-157 or saline, after which a blinded evaluator will assess shoulder strength. The listing states the pilot's objectives: to assess safety and protocol feasibility and to inform the design of a future, larger trial that would determine whether BPC-157 actually works. The study description itself acknowledges: "...it has not been studied in formal clinical trials in humans." In practice, the trial is being run by the University of Arkansas for Medical Sciences (UAMS) in Little Rock, not the parent University of Arkansas that appears as the listed sponsor.
Other sources confirm the scale of this evidence gap. Across the entire global clinical trials registry, BPC-157 is listed as the intervention in just four registered studies, the Arkansas trial included. A 2025 systematic review in the peer-reviewed orthopedic journal HSS Journal identified 36 relevant studies on BPC-157: 35 were animal experiments, and the sole human study was a small retrospective observation without placebo or randomization, in which 7 of 12 patients with chronic knee pain reported improvement after injection.
In July, an FDA advisory committee voted 8 to 6 in favor of adding BPC-157 to the list of substances eligible for pharmacy compounding, overriding the agency staff's recommendation to reject all peptides under consideration. Against this backdrop, the trial record appeared in the registry on September 3, and the social media wave about the "launch" rose only three weeks later, a typical lag for niche authors to notice fresh ClinicalTrials.gov listings. Avi Roy responded two days after Swiergol's post.
A registry listing confirms only the intention to conduct a trial: a protocol that still has to be carried out. The substance is already sold legally, injected by thousands of people without any oversight, and under review by regulators as a candidate for pharmacy shelves, while its first controlled test in humans is still being prepared.